Navigation Links
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Date:5/10/2013

NSI-566, was approved by the FDA to commence a Phase I trial to treat chronic spinal cord injury (cSI). This open-label, multi-site study will enroll up to eight patients with thoracic spinal cord injuries (T2-T12) who have an American Spinal Injury Association AIS-A level of impairment, between one and two years post injury. These patients exhibit no motor or sensory function in the relevant segments at and below the injury, and are considered to be in complete paralysis. Study patients will receive six injections in, or around, the injury site: the first four patients will receive 100,000 cells per injection; the second four patients, 200,000 cells per injection. All NSI-566/cSCI patients will receive post-surgery physical therapy, as well as immunosuppressive therapy, which will be for three months, as tolerated. The trial study period will end six months post-surgery for each patient. The primary objective of the study is to determine the safety and toxicity of NSI-566 for the treatment of paralysis and related symptoms due to cSCI. The secondary objectives are to evaluate graft survival in the transplant site by MRI, as well as the effectiveness of transient immunosuppression.

In January, Neuralstem received issuance of U.S. Patent #8,362,262, Divisional Compositions and Methods of Use, part of the small molecule IP; additionally, issuance of PCT Patent #2337517, Floating Cannula and Method of Use, which is exclusively licensed by Neuralstem, and validated in four European countries: Germany, France, Italy and United Kingdom, for a total of five European patents.

In February, Neuralstem's NSI-566 Phase I Clinical Trial in ALS (amyotrophic lateral sclerosis, or Lou Gehrig 's disease) officially concluded, six months after the final surgery at Emory University Hospital.

In February, Neuralstem granted li
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
2. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
3. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
4. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
5. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
6. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
7. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
8. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
9. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
10. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
11. Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 In 2013, Lawrence ... Livermore National Security LLC (LLNS), was awarded ... a state-of-the-art laser system for the European Union's ... construction in the Czech Republic. , When commissioned ... called the " High repetition-rate Advanced Petawatt Laser ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Global Biodegradable Packaging ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable Packaging ... readily decomposed by the action of microorganisms. ... in terms of raw materials, production technology, ...
(Date:8/27/2014)... , Aug. 27, 2014   MSC , a ... safety, today announced the appointment of Mary Beth ... With 28 years of experience preparing companies for rapid ... as Executive Vice President of Corporate Development and Healthcare. ... improvement business , as well as corporate strategy and ...
(Date:8/27/2014)... One of nature,s mysteries is how plants survive ... in the sun,s rays, while using this energy ... proteins in the plant,s blades quickly dissipate the ... protein quakes. Researchers at DTU Physics have now ... plants, algae and bacteria contain light-absorbing proteins which ...
Breaking Biology Technology:LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7MSC names Mary Beth Loesch President and CEO 2DTU researchers film protein quake for the first time 2
... Calif., Aug. 25, 2011 Emmy® and Tony® award-winning ... ) today launch Act 2 Reduce Fractures™, an educational ... for fractures. Earlier this year, Danner was diagnosed with ... to encourage women like her to educate themselves, take ...
... 25, 2011 SyntheMed, Inc. (OTC Bulletin Board: ... announced that its stockholders approved the planned merger with ... today.  In excess of 99% of the votes cast ... merger with Pathfinder was previously announced and is described ...
... Hikma Pharmaceuticals reports lower-than-expected 3.2% increase in revenues ... The international drug developer says that political ... some key countries like Egypt and Tunisia. ... Hikma CEO Said Darwazah says that production is back ...
Cached Biology Technology:Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign 2Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign 3Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign 4Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign 5Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign 6Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign 7SyntheMed, Inc. Announces Stockholder Approval of Planned Merger With Pathfinder, LLC 2SyntheMed, Inc. Announces Stockholder Approval of Planned Merger With Pathfinder, LLC 3
(Date:8/27/2014)... , Aug. 27, 2014  WaferGen Bio-systems, Inc. ... previously announced underwritten public offering of units of common ... unit for gross proceeds of $20 million, prior to ... by the Company.  The shares and warrants are immediately ... Each unit sold in the offering consists of 2,000 ...
(Date:8/27/2014)... mastodons, short-faced bears, giant ground sloths, saber-toothed cats and ... years ago at the end of the Pleistocene period. ... debated by scientists who, until recently, could only speculate ... UC Santa Barbara,s James Kennett, professor emeritus in the ... with Earth played a major role in the extinction. ...
(Date:8/27/2014)... big step in understanding the mysteries of the human ... analyses that provide the most detailed comparison yet of ... human function. , The research, appearing August 28 ... the information encoded in the three species, genomes is ... organized into chromosomes. , The results add billions of ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Nanodiamonds are forever 2Nanodiamonds are forever 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4
... COMO, ITALY -- Traditionally addressed through hand-weeding and/or herbicide ... in nursery production. Increased labor costs have made hand-weeding ... although herbicides may be effective and less expensive, non-target ... can harm the environment. To address the economic and ...
... of extinction until Lindsay Oaks and Richard Watson, from The ... to find out why the number of birds was falling ... residues of an anti-inflammatory drug (diclofenac) used in cattle and ... presented in a chapter of the new book, ,Wildlife Ecotoxicology ...
... German . , Flies are real flight ... body size. Scientists at the Max Planck Institute of Biochemistry ... that regulates the formation of flight muscles. "The gene spalt ... emphasizes Frank Schnorrer, head of the research group ,Muscle Dynamics,. ...
Cached Biology News:Biodegradable mulches successfully control weeds in container-grown arborvitae 2Vultures dying at alarming rate 2How the fly flies 2
... SR-101 Labeled Substrates (red fluorescence; Ex=590 ... serine protease activation • No lysing, ... Kits utilize cell-permeable, fluorescently labeled inhibitors ... chymotrypsin-like activity in whole living cells. ...
... thermal cycler with 384-well reaction module is ... It is equipped with an interchangeable, 384-well ... algorithm temperature monitoring and control and ramp ... volumes. It includes the iCycler base with ...
... The DNA Engine instrument is ... Unprecedented thermal uniformity and ... and block-to-block. This rugged ... cycler, it's a platform for new ...
Request Info...
Biology Products: